



# Ikonisys

Med Tech / France

## Factoring in the revised commercialisation plans

Update - 22/10/2021

### Change in EPS

2021 : € -0.02 vs -0.03	ns
2022 : € -0.30 vs -0.40	ns

Given the delayed equipment sales and associated recurring sales stream, coupled with higher R&D expenses, our assumption of medium-term losses has been maintained.

### Change in NAV

€ 16.1 vs 18.5	-13.0%
----------------	--------

While the multiples for the respective divisions remain unchanged, the NAV downgrade is largely a function of commercialisation delays. Although the NAV remains the most-attractive metric reflecting the firm's long-term potential, assuming that business plans are gradually back on track.

### Change in DCF

€ 8.23 vs 9.77	-15.7%
----------------	--------

Factoring in the medium-term business challenges, the DCF resets lower. This metric's higher sensitivity (vis-à-vis NAV) is also due to cash flows in the medium term. Hence, the plans hinge on easy access to capital markets, at least while reasonable-to-healthy earnings/cash flows haven't been restored. Nevertheless, the healthy out-year growth estimates have been maintained, given the focus on the market's potential and Ikonisys' valued differentiation.



Anas PATEL


health@alphavalue.eu  
+33 (0) 1 70 61 10 50  
cs.alphavalue.com

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

### Buy Upside : 262%

Target Price (6 months)	€ 10.00
Share Price	€ 2.76
Market Cap. €M	26.2

Price Momentum	
Extremes 12Months	2.75 ▶ 4.59
Bloomberg	ALIKO FP Equity
Reuters	ALIKO.PA



[Download Full Analysis](#)
[Company Page](#)


PERF	1w	1m	3m	12m
Ikonisys	-3.83%	-4.83%	-37.4%	n/a
Health	4.18%	-3.61%	4.88%	28.5%
SXXR Index	0.84%	2.53%	3.91%	33.1%

Last updated: 22/10/2021	12/20A	12/21E	12/22E	12/23E
Adjusted P/E (x)	-15.4	ns	-9.25	-48.9
Dividend yield (%)	0.00	0.00	0.00	0.00
EV/EBITDA(R) (x)	ns	ns	-9.96	-79.0
Adjusted EPS (€)	-0.18	-0.02	-0.30	-0.06
Growth in EPS (%)	n/a	n/a	n/a	n/a
Dividend (€)	0.00	0.00	0.00	0.00
Sales (€M)	0.39	0.35	4.14	7.99
Other margin (%)	97.9	75.0	47.1	57.3
Attributable net profit (€M)	-1.57	-0.18	-2.83	-0.54
ROE (after tax) (%)	-27.7	-2.40	-36.3	-8.76
Gearing (%)	16.1	-2.75	2.17	44.1

[Company Valuation](#) - [Company Financials](#)

## Sales by Geography



■ North America (100.0%)

## Consolidated P&L Accounts

		12/20A	12/21E	12/22E
Sales	€M	0.39	0.35	4.14
Change in sales	%	-37.6	-8.52	1,074
Change in staff costs	%	1.01	50.0	90.0
EBITDA	€M	0.17	-0.23	-2.81
<b>EBITDA(R) margin</b>	<b>%</b>	<b>44.9</b>	<b>-65.0</b>	<b>-67.9</b>
Depreciation	€M	-0.07	0.00	0.00
Underlying operating profit	€M	0.10	-0.23	-2.81
<b>Operating profit (EBIT)</b>	<b>€M</b>	<b>0.20</b>	<b>-0.13</b>	<b>-2.81</b>
Net financial expense	€M	-1.77	-0.04	-0.01
of which related to pensions	€M	0.00	0.00	0.00
Exceptional items & other	€M			
Corporate tax	€M	-0.01	0.00	-0.01
Equity associates	€M			
Minority interests	€M			
<b>Adjusted attributable net profit</b>	<b>€M</b>	<b>-1.57</b>	<b>-0.18</b>	<b>-2.83</b>
NOPAT	€M	0.07	-0.16	-1.97

## Cashflow Statement

EBITDA	€M	0.17	-0.23	-2.81
Change in WCR	€M	0.15	-1.09	-0.62
Actual div. received from equity holdi...	€M	0.00	0.00	0.00
Paid taxes	€M	-0.01	0.00	-0.01
Exceptional items	€M			
Other operating cash flows	€M	-2.62	0.10	0.00
Total operating cash flows	€M	-2.31	-1.22	-3.45
Capital expenditure	€M	0.00	-0.01	-0.06
Total investment flows	€M	0.00	-0.01	-0.06
Net interest expense	€M	-1.77	-0.04	-0.01
Dividends (parent company)	€M			
Dividends to minorities interests	€M	0.00	0.00	0.00
New shareholders' equity	€M	0.09	4.00	0.00
Total financial flows	€M	2.03	3.01	3.69
Change in cash position	€M	-0.14	1.79	0.19
<b>Free cash flow (pre div.)</b>	<b>€M</b>	<b>-4.08</b>	<b>-1.27</b>	<b>-3.51</b>

## Per Share Data

No. of shares net of treas. stock (year...	Mio	8.78	9.48	9.48
Number of diluted shares (average)	Mio	8.78	9.13	9.48
<b>Benchmark EPS</b>	<b>€</b>	<b>-0.18</b>	<b>-0.02</b>	<b>-0.30</b>
Restated NAV per share	€			
<b>Net dividend per share</b>	<b>€</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>

## Valuation Summary

Benchmarks	Value	Weight	Largest comparables
DCF	€ 8.23	40%	● Qiagen
NAV/SOTP per share	€ 16.1	40%	
P/E	€ 1.38	5%	
EV/Ebitda	€ 0.00	5%	
P/Book	€ 3.79	5%	
Dividend Yield	€ 0.00	5%	
TARGET PRICE	€ 10.00	100%	

### NAV/SOTP Calculation

## Balance Sheet

		12/20A	12/21E	12/22E
Goodwill	€M	4.42	4.42	4.42
Total intangible	€M	7.92	7.92	7.92
Tangible fixed assets	€M	0.00	0.01	0.07
Financial fixed assets	€M			
WCR	€M	-1.03	0.05	0.68
Other assets	€M	0.03	0.03	0.03
Total assets (net of short term liab.)	€M	7.01	8.10	8.79
<b>Ordinary shareholders' equity</b>	<b>€M</b>	<b>5.39</b>	<b>9.21</b>	<b>6.38</b>
Quasi Equity & Preferred	€M	0.27	0.27	0.27
Minority interests	€M			
Provisions for pensions	€M	0.00	0.00	0.00
Other provisions for risks and liabilities	€M			
Total provisions for risks and liabilities	€M	0.00	0.00	0.00
Tax liabilities	€M			
Other liabilities	€M	0.23	0.23	0.23
<b>Net debt (cash)</b>	<b>€M</b>	<b>1.11</b>	<b>-1.62</b>	<b>1.90</b>
Total liab. and shareholders' equity	€M	7.01	8.10	8.79

## Capital Employed

Capital employed after depreciation	€M	6.89	7.98	8.67
-------------------------------------	----	------	------	------

## Profits & Risks Ratios

<b>ROE (after tax)</b>	%	<b>-27.7</b>	<b>-2.40</b>	<b>-36.3</b>
ROCE	%	1.07	-2.02	-22.7
<b>Gearing (at book value)</b>	<b>%</b>	<b>16.1</b>	<b>-2.75</b>	<b>2.17</b>
Adj. Net debt/EBITDA(R)	x	6.43	7.06	-0.68
Interest cover (x)	x	0.06	-5.17	-4.14

## Valuation Ratios

<b>Reference P/E (benchmark)</b>	<b>x</b>	<b>-15.4</b>	<b>ns</b>	<b>-9.25</b>
Free cash flow yield	%	-16.8	-4.85	-13.4
P/Book	x	4.50	2.84	4.10
<b>Dividend yield</b>	<b>%</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>

## EV Calculation

Market cap	€M	24.2	26.2	26.2
+ Provisions	€M	0.00	0.00	0.00
+ Unrecognised actuarial losses/(gains)	€M	0.00	0.00	0.00
+ Net debt at year end	€M	1.04	-1.70	1.82
+ Leases debt equivalent	€M	0.00	0.00	0.00
- Financial fixed assets (fair value)	€M	0.01	0.01	0.01
+ Minority interests (fair value)	€M			
= EV	€M	25.3	24.5	28.0
<b>EV/EBITDA(R)</b>	<b>x</b>	<b>ns</b>	<b>ns</b>	<b>-9.96</b>
EV/Sales	x	65.6	69.4	6.76

Analyst : Anas Patel, Changes to Forecasts : 22/10/2021.